ATE373730T1 - Verwendung von humanen oatp-c polymorphismen, die einen effekt auf die pharmakokinetik von statin haben, bei der statin-therapie - Google Patents

Verwendung von humanen oatp-c polymorphismen, die einen effekt auf die pharmakokinetik von statin haben, bei der statin-therapie

Info

Publication number
ATE373730T1
ATE373730T1 AT04743565T AT04743565T ATE373730T1 AT E373730 T1 ATE373730 T1 AT E373730T1 AT 04743565 T AT04743565 T AT 04743565T AT 04743565 T AT04743565 T AT 04743565T AT E373730 T1 ATE373730 T1 AT E373730T1
Authority
AT
Austria
Prior art keywords
statin
polymorphisms
pharmacokinetics
effect
oatp
Prior art date
Application number
AT04743565T
Other languages
German (de)
English (en)
Inventor
Helen Ambrose
Ruth March
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE373730T1 publication Critical patent/ATE373730T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Semiconductor Lasers (AREA)
AT04743565T 2003-07-26 2004-07-26 Verwendung von humanen oatp-c polymorphismen, die einen effekt auf die pharmakokinetik von statin haben, bei der statin-therapie ATE373730T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0317592.4A GB0317592D0 (en) 2003-07-26 2003-07-26 Method

Publications (1)

Publication Number Publication Date
ATE373730T1 true ATE373730T1 (de) 2007-10-15

Family

ID=27772801

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04743565T ATE373730T1 (de) 2003-07-26 2004-07-26 Verwendung von humanen oatp-c polymorphismen, die einen effekt auf die pharmakokinetik von statin haben, bei der statin-therapie

Country Status (12)

Country Link
US (1) US7700277B2 (enExample)
EP (1) EP1651774B1 (enExample)
JP (1) JP4166257B2 (enExample)
AT (1) ATE373730T1 (enExample)
CY (1) CY1107801T1 (enExample)
DE (1) DE602004009083T2 (enExample)
DK (1) DK1651774T3 (enExample)
ES (1) ES2291899T3 (enExample)
GB (1) GB0317592D0 (enExample)
PL (1) PL1651774T3 (enExample)
PT (1) PT1651774E (enExample)
WO (1) WO2005012566A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1784504A2 (en) * 2004-07-21 2007-05-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Oatp-c gene c463a polymorphism underlies variable response of statin therapy
CN102016073A (zh) 2008-02-29 2011-04-13 Isis创新有限公司 诊断方法
US9817001B2 (en) 2008-05-27 2017-11-14 Boston Heart Diagnostics Corporation Methods for determining LDL cholesterol treatment
US8470541B1 (en) 2008-09-27 2013-06-25 Boston Heart Diagnostics Corporation Methods for separation and immuno-detection of biomolecules, and apparatus related thereto
WO2013056087A2 (en) * 2011-10-13 2013-04-18 Boston Heart Diagnostics Compositions and methods for treating and preventing coronary heart disease
US9828624B2 (en) 2013-07-24 2017-11-28 Boston Heart Diagnostics Corporation Driving patient compliance with therapy
EP3220810A4 (en) 2014-11-17 2018-05-16 Boston Heart Diagnostic Corporation Cardiovascular disease risk assessment
US10572811B2 (en) 2015-01-29 2020-02-25 Splunk Inc. Methods and systems for determining probabilities of occurrence for events and determining anomalous events
CA3100035A1 (en) 2018-08-27 2020-03-05 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
CN110904215A (zh) * 2019-12-16 2020-03-24 西安和合医学检验所有限公司 用于同步检测slco1b1基因的两个snp位点的基因多态性的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US32011A (en) * 1861-04-09 Coffee-pot
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
GB8902689D0 (en) 1989-02-07 1989-03-30 Ici Plc Assay method
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
CA2176348C (en) 1993-11-12 2004-11-02 Sanjay Tyagi Hybridization probes for nucleic acid detection, universal stems, methods and kits
WO2000008157A2 (en) 1998-08-07 2000-02-17 Axys Pharmaceuticals, Inc. Human anion transporter genes atnov
US20020090622A1 (en) 2000-08-23 2002-07-11 Monisola Adeokun Chemical compounds

Also Published As

Publication number Publication date
WO2005012566A3 (en) 2005-06-16
US7700277B2 (en) 2010-04-20
WO2005012566A2 (en) 2005-02-10
EP1651774B1 (en) 2007-09-19
DE602004009083T2 (de) 2008-06-19
DE602004009083D1 (de) 2007-10-31
EP1651774A2 (en) 2006-05-03
DK1651774T3 (da) 2008-01-07
ES2291899T3 (es) 2008-03-01
PL1651774T3 (pl) 2007-12-31
JP4166257B2 (ja) 2008-10-15
PT1651774E (pt) 2007-11-16
US20070031838A1 (en) 2007-02-08
GB0317592D0 (en) 2003-08-27
JP2007500005A (ja) 2007-01-11
CY1107801T1 (el) 2013-06-19

Similar Documents

Publication Publication Date Title
CY1107801T1 (el) Χρηση πολυμορφισμων στον ανθρωπινο oatp-c που σχετιζονται με μια επιδραση στη φαρμακοκινητικη στατινης σε ανθρωπους σε θεραπεια στατινης
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
BR0313330A (pt) Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4
DE60319158D1 (de) Pyrazoloisoquinolinenderivaten als kinase inhibitoren
DE602004021838D1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
HRP20050228A2 (en) Novel phenanthridines
MXJL05000010A (es) Compuestos de fenil-aza-benzimidazol para modular la ige e inhibir la proliferacion celular.
DE60314600D1 (de) O-cyclopropyl-carboxanilide und ihre verwendung als fungizide
DE602004015269D1 (de) Piperazin derivate und ihre verwendung für die behandlung von neurologischen und psychiatrischen krankheiten.
DE69836563D1 (de) INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYLSUBSTITUIERTEN HARNSTOFFEN
ATE556713T1 (de) Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
DE602004026113D1 (de) Glp-1-verbindungen
PT1206474E (pt) Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
BRPI0410289A (pt) ligantes do receptor de canabinóides e suas utilizações
ATE508114T1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
WO2005016883A3 (en) Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
ATE413392T1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
DE602005017626D1 (de) Antivirale verwendung von borinsäurekomplexen
DE60309344D1 (de) Derivate von ä6, 7-dihydro -5h-imidazoä1,2 - aüimidazol -3 -sulfonylaminoü-propionamid und deren verwendung als inhibitoren der interaktion von cams und leukointreginen
SE0301654D0 (sv) Novel compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1651774

Country of ref document: EP